Table 1.
Patient ANA and autoantibody profile at enrolment and year five (n=805)
| Enrolment | Year 5 | Difference1 (95% CI) | |
|---|---|---|---|
| ANA ICAP Pattern | % | % | |
| AC-0 (No staining) | 1.7 | 1.1 | −0.6 (−1.9, 06) |
| AC-1 | 34.9 | 30.1 | −4.8 (−8.4, −1.3) |
| AC-2 | 1.1 | 1.2 | 0.1 (−0.8, 1.1) |
| AC-3 | 1.1 | 1.4 | 0.2 (−0.6, 1.1) |
| AC-4 | 39.4 | 47.5 | 8.1 (3.5, 12.6) |
| AC-5 (includes nuclear matrix pattern) | 34.4 | 36.1 | 1.7 (−2.2, 5.6) |
| AC-6 | 0.6 | 0.5 | −0.1 (−1.0, 0.7) |
| AC-7 | 4.0 | 5.7 | 1.7 (−0.2, 3.7) |
| AC-8 | 2.6 | 3.2 | 0.6 (−1.1, 2.3) |
| AC-9 | 0.5 | 1.2 | 0.7 (−0.2, 1.7) |
| AC-10 | 7.2 | 8.4 | 1.2 (−1.3, 3.8) |
| AC-11 | 0.1 | 0.4 | 0.2 (−0.3, 0.9) |
| AC-12 | 1.5 | 1.1 | −0.4 (−1.6, 0.9) |
| AC-13 | 0.2 | 0.2 | 0 (−0.6, 0.6) |
| AC-14 | 0 | 0 | 0 (−0.1, 0.1) |
| AC-15 | 0.2 | 0 | −0.2 (−0.7, 0.2) |
| AC-16 | 0.2 | 0.4 | 0.1 (−0.5, 0.7) |
| AC-17 | 0.2 | 0.2 | 0 (−0.5, 0.5) |
| AC-18 | 1.5 | 1.1 | −0.4 (−1.5, 0.7) |
| AC-19 | 13.8 | 17.5 | 3.7 (0.6, 6.9) |
| AC-20 | 12.4 | 12.2 | −0.2 (−3.5, 3.0) |
| AC-21 | 5.8 | 4.7 | −1.1 (−3.0, 0.8) |
| AC-22 | 0.2 | 0.1 | −0.1 (−0.7, 0.4) |
| AC-23 | 0.1 | 0.2 | 0.1 (−0.4, 0.7) |
| AC-24 | 2.0 | 3.6 | 1.6 (0.1, 3.1) |
| AC-25 | 0.1 | 0.1 | 0 (−0.1, 0.1) |
| AC-26 | 0.4 | 0.6 | 0.2 (−0.6, 1.1) |
| AC-27 | 1.5 | 0.9 | −0.6 (−1.7, 0.4) |
| AC-28 | 0.2 | 0.2 | 0 (−0.6, 0.6) |
| AC-29 | 0.1 | 0 | −0.1 (−0.5, 0.2) |
| Autoantibodies, % | |||
| dsDNA2 | 34.2 | 29.1 | −5.1 (−8.7, −1.6) |
| Ribosomal P | 24.3 | 20 | −4.3 (−7.8, −0.9) |
| Ro52/TRIM21 | 37.5 | 37.4 | −0.1 (−3.4, 3.2) |
| SSA/Ro60 | 42.5 | 42.0 | −0.5 (−3.7, 2.7) |
| SSB/La | 20.7 | 16.3 | −4.5 (−7.5, −1.5) |
| Sm | 22.7 | 14.7 | −8.1 (−11.1, −5.0) |
| U1RNP | 28.2 | 23.0 | −5.2 (−8.5, −2.0) |
| Histones | 31.3 | 22.7 | −8.6 (−12.1, −5.0) |
| Jo-1 | 1.5 | 3.7 | 2.2 (0.7, 3.7) |
| Centromere B | 2.7 | 5.5 | 2.7 (0.9, 4.5) |
| PCNA | 15.8 | 18.4 | 2.6 (−0.9, 6.1) |
| DFS70 | 6.1 | 6.0 | −0.1 (−1.3, 1.1) |
| Cardiolipin IgG/IgM3 | 20.5 | 16.4 | −4.0 (−7.5, −0.4) |
| β2GP1 IgG/IgM3 | 19.9 | 12.9 | −7.0(−9.9, −4.1) |
| Lupus anticoagulant4 | 19.5 | 14.2 | −5.3 (−8.3, −2.2) |
| PS/PT IgG/IgM | 36.3 | 26.0 | −10.3 (−13.9, −6.7) |
| β2GP1-Domain 1 | 10.3 | 7.8 | −2.5 (−4.8, −0.2) |
Abbreviations: AC, anti-cellular pattern according to ICAP nomenclature; ACR, American College of Rheumatology; ANA, anti-nuclear antibodies; β2GP1, β2-glycoprotein-1; CI, confidence interval; DFS, dense fine speckled; dx, diagnosis; dsDNA, double-stranded DNA; ICAP, International Consensus on ANA Patterns; IgG/M, immunoglobulin G/immunoglobulin M; Jo-1, histidyl tRNA synthetase; PCNA, proliferating cell nuclear antigen; PS/PT, phosphatidyl serine-prothrombin complex; RNP, ribonucleoprotein; SD, standard deviation; SLEDAI-2K, systemic lupus erythematosus disease activity index-2000; SDI, SLICC Damage index; Sm, Smith antigen (U2-U6 RNP); SSA, Sjögren syndrome antigen A or Ro60: SSB, Sjögren syndrome antigen B or La: TRIM21, Tripartite Motif Protein (TRIM) 21; yrs, years.
Difference between enrolment and year 5 visit
Complete data available for n=798 patients
Complete data available for n= 800
Complete data available for n=282